Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II of Neoadjuvant Olaparib in Combination with Pembrolizumab in Patients with Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer and Germline Mutations in DNA Damage Repair Genes

Next Previous
Search
Trial Profile

Phase II of Neoadjuvant Olaparib in Combination with Pembrolizumab in Patients with Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer and Germline Mutations in DNA Damage Repair Genes

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
  • Indications Breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Jan 2025 Status changed from recruiting to active, no longer recruiting.
    • 27 Dec 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.
    • 27 Dec 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top